ArticleCancers2018

The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.

Katja Seipel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.